VRDN Management Vocally Bullish On IV, Investors Still Not Fully Convinced. Good setup

Research evidence excerpt

VRDN Management Vocally Bullish On IV, Investors Still Not Fully Convinced. Good setup

Biotechnology - Immunology

FLASH

FLASH: VIRIDIAN THERAPEUTICS, INC. (VRDN) June 29, 2026

VRDN Management Vocally Bullish On IV, Investors Still Rating:

Not Fully Convinced. Good setup Outperform

Price:

News Lumvoa approved treatment for TED with labeling that includes data for both $17.90

active and chronic. Viridian plans to launch Lumvoa immediately, with subcutaneous Price Target:

$22elegrobart on track for a BLA submission in Q1 2027. The company priced at parity % Upside:

on a course of therapy basis with Tepezza (Wolfe: excellent buy-and-bill incentive). 22.9%

Expects most coverage decisions within 6-9months post launch. VirdianCares is live

Source: FactSet, Wolfe Research

today and accepting enrollments. Priced as of 06/26/26

Commentary from Viridian. Viridian is very bullish on Lumvoa's peak potential and

believes that the time to peak will be 'rapid.' The company expects early use in the

active population & sees the possibility for patients to start in the first couple of

quarters (vast majority of patients are in infusion centers who are used to dealing

with temp J-codes). Does not expect much stocking, given just-in-time inventory Andy Chen, PhD CFA

(possibly modest in the early days) and infusion centers order on a dose-by-dose achen@wolferesearch.com

basis. Company plans to share enrollment forms & aiming to convert the 2000 existing 646-582-9370 View Andy’s Research

prescribers. Would not draw any conclusions from the first few quarters of Tepezza View VRDN Model

launch (argues that the circumstances are drastically different), but believes that View Comp Table

their market research suggests that prescribers are excited to try Lumvoa. Does not

Brandon Frith